Examination of metallic impurities of 68Ge/68Ga generators used for radioactive labeling of peptides in clinical PET applications

Good practices for 68Ga radiopharmaceutical production

Background

The radiometal gallium-68 (⁶⁸Ga) is increasingly used in diagnostic positron emission tomography (PET), with ⁶⁸Ga-labeled radiopharmaceuticals developed as potential higher-resolution imaging alternatives to traditional ^99mTc agents. In precision medicine, PET applications of ⁶⁸Ga are widespread, with ⁶⁸Ga radiolabeled to a variety of radiotracers that evaluate perfusion and organ function, and target specific biomarkers found on tumor lesions such as prostate-specific membrane antigen, somatostatin, fibroblast activation protein, bombesin, and melanocortin.

Main body

These ⁶⁸Ga radiopharmaceuticals include agents such as [⁶⁸Ga]Ga-macroaggregated albumin for myocardial perfusion evaluation, [⁶⁸Ga]Ga-PLED for assessing renal function, [⁶⁸Ga]Ga-t-butyl-HBED for assessing liver function, and [⁶⁸Ga]Ga-PSMA for tumor imaging. The short half-life, favourable nuclear decay properties, ease of radiolabeling, and convenient availability through germanium-68 (⁶⁸Ge) generators and cyclotron production routes strongly positions ⁶⁸Ga for continued growth in clinical deployment. This progress motivates the development of a set of common guidelines and standards for the ⁶⁸Ga radiopharmaceutical community, and recommendations for centers interested in establishing ⁶⁸Ga radiopharmaceutical production.

Conclusion

This review outlines important aspects of ⁶⁸Ga radiopharmacy, including ⁶⁸Ga production routes using a ⁶⁸Ge/⁶⁸Ga generator or medical cyclotron, standardized ⁶⁸Ga radiolabeling methods, quality control procedures for clinical ⁶⁸Ga radiopharmaceuticals, and suggested best practices for centers with established or upcoming ⁶⁸Ga radiopharmaceutical production. Finally, an outlook on ⁶⁸Ga radiopharmaceuticals is presented to highlight potential challenges and opportunities facing the community.

High-Efficiency Cationic Labeling Algorithm of Macroaggregated Albumin with 68Gallium

Purpose

The generator product radionuclide gallium-68(⁶⁸Ga) is widely used for PET/CT imaging agents and the ⁶⁸Ga-labeled MAA is an attractive alternative to ^99mTc-labeled MAA. Using a commercially available MAA labeling kit for ^99mTc, we presented a reliable synthesis protocol with a highly efficient, organic solvent-free cationic method in GMP conditions in the Scintomics automated synthesis unit.

Methods

The labeling process was performed by incubating for 7 min at 90 ^°C in the borax vial containing the generator product ⁶⁸GaCl₃ MAA-HEPES eluted from the PSH⁺ cartridge with 1.5 mL 5 molar NaCl. Quality control of the final product content was examined, and radiopharmaceutical production was carried out in accordance with GMP guidelines.

Results

⁶⁸Ga eluted from the generator was obtained in more than 99% radiochemical purity and efficiency. In this case, the labeling efficiency was found to be >99%. When the results of SEM-EDX analysis in the final product were examined, it was determined that most of toxic metals were no appreciable in the product content.

Conclusions

The radiochemical and chemical purity of the final product allows direct use without purification steps to remove "free ⁶⁸Ga" or other toxic compounds.